Recent drug therapies for corneal neovascularization

被引：34

作者：

Liu, Xinyao ^{[1
]}

Wang, Shurong ^{[1
]}

Wang, Xuanzhong ^{[1
]}

Liang, Jiaming ^{[1
]}

Zhang, Yan ^{[1
]}

机构：

[1] Jilin Univ, Dept Ophthalmol, Teaching Hosp 2, Changchun, Jilin, Peoples R China

来源：

CHEMICAL BIOLOGY & DRUG DESIGN | 2017年 / 90卷 / 05期

关键词：

corneal neovascularization; drug; inhibitor; treatment; vascular endothelial growth factor; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE ACETONIDE; TYROSINE KINASE INHIBITOR; SUBCONJUNCTIVAL BEVACIZUMAB; MOUSE-MODEL; CYCLOSPORINE-A; ASCORBIC-ACID; MATRIX METALLOPROTEINASE-2; EPIGALLOCATECHIN GALLATE; RANIBIZUMAB LUCENTIS;

D O I：

10.1111/cbdd.13018

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Corneal neovascularization (CNV) is a common pathological change in ocular surface diseases. It is not only the factor that affects vision but also the main cause for corneal graft failure. Based on the mechanism of CNV, many achievements have been developed to suppress the formation of CNV. There are certain novel drugs such as aflibercept, gold nanoparticles, and netrins which provide us with new clues to treat CNV. However, we still need to develop more effective therapeutic drugs. It is of great significance to develop new effective drugs to suppress the occurrence of CNV. In this paper, recent drug therapies for CNV are reviewed. The electronic database (PubMed) is searched for relative basic research and randomized clinical trials that are published recently.

引用

页码：653 / 664

页数：12

共 148 条

[1] Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model [J].

Akar, Ebru Eren ;

Oner, Veysi ;

Kucukerdonmez, Cem ;

Akova, Yonca Aydin .

INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2013, 6 (02) :136-140

[2]

Ambati BK, 2002, ARCH OPHTHALMOL-CHIC, V120, P1063

[3] Safety and Efficacy of the Multitargeted Receptor Kinase Inhibitor Pazopanib in the Treatment of Corneal Neovascularization [J].

Amparo, Francisco ;

Sadrai, Zahra ;

Jin, Yiping ;

Alfonso-Bartolozzi, Belen ;

Wang, Haobing ;

Shikari, Hasanain ;

Ciolino, Joseph B. ;

Chodosh, James ;

Jurkunas, Ula ;

Schaumberg, Debra A. ;

Dana, Reza .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (01) :537-544

[4] Antitumor/Antiestrogenic Effect of the Chemokine Interferon Inducible Protein 10 (IP-10) Involves Suppression of VEGF Expression in Mammary Tissue [J].

Aronica, Susan M. ;

Raiber, Lisa ;

Hanzly, Michael ;

Kisela, Caroline .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2009, 29 (02) :83-91

[5] Subconjunctival bevacizumab lnjection for corneal neovascularization [J].

Bahar, Irit ;

Kaiserman, Igor ;

McAllum, Penny ;

Rootman, David ;

Slomovic, Allan .

CORNEA, 2008, 27 (02) :142-147

[6] Cytotoxic Properties of Sunitinib and Sorafenib on Human Corneal Epithelial Cells [J].

Bayyoud, Tarek ;

Hofmann, Johanna ;

Spitzer, Martin ;

Bartz-Schmidt, Karl Ulrich ;

Yoeruek, Efdal .

CURRENT EYE RESEARCH, 2014, 39 (02) :149-154

[7]

Beerepoot LV, 2003, CLIN CANCER RES, V9, P4025

[8]

BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954

[9] Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions [J].

Biagi, C. ;

Conti, V. ;

Montanaro, N. ;

Melis, M. ;

Buccellato, E. ;

Donati, M. ;

Covezzoli, A. ;

Amato, R. ;

Pazzi, L. ;

Venegoni, M. ;

Vaccheri, A. ;

Motola, D. .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (12) :1505-1512

[10] An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty [J].

Birnbaum, F ;

Reis, A ;

Böhringer, D ;

Sokolowska, Y ;

Mayer, K ;

Voiculescu, A ;

Oellerich, M ;

Sundmacher, R ;

Reinhard, T .

TRANSPLANTATION, 2006, 81 (05) :767-772

← 1 2 3 4 5 6 7 8 9 10 →